Clinical trials: GIST
Gastrointestinal Stromal Tumors
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in patients with gastrointestinal stromal tumor (GIST).
- Trial name
- NCT05080621
- Testing
- Ripretinib, binimetinib
- Sponsor
- Deciphera Pharmaceuticals, LLC
Sarcoma, Malignant Gastrointestinal Stromal Tumor
Phase II Trial of Locally Advanced/Metastatic Soft Tissue Sarcoma or Advanced/Metastatic Malignant GIST
Study Design Type of Study This is an open-label, single arm, prospective, multiple-center phase II study Duration of the Study Period in One Subject Treatment duration is planned for six cycles, unless there is evidence of…
- Trial name
- STS (NCT00359333)
- Testing
- Gemcitabine , Docetaxel
- Where
- Taiwan
- Volunteers
- 58 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Stromal Tumors, Cancer Brain
Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients
Imatinib (IM) has dramatically improved survival of gastrointestinal stromal tumors (GIST). However, most patients become resistant to IM in less than two years.
- Conditions
- Gastrointestinal Stromal Tumors, Cancer Brain, Solid Tumors
- Trial name
- NCT00585221
- Testing
- Peginterferon-alpha 2b (PegIFNa2b);, Imatinib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Gastrointestinal Stromal Tumor, Metastatic Cancer
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and to see how well it works…
- Trial name
- GISTs (NCT00764595)
- Testing
- imatinib mesylate
- Where
- 36 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Gastrointestinal Stromal Tumor (GIST)
Oncogenetic Panel and Integrated Clinical Data Registry Study for Wild Type Gastrointestinal Stromal Tumor Patients
The genetic background for cancer treatment may also be different among different areas and races. There is lack of Taiwanese data of genetic alterations in cancer patients.
- Trial name
- GIST (NCT04821895)
- Where
- 11 sites in Taiwan
- Volunteers
- 50 people
- Sponsor
- National Health Research Institutes, Taiwan
Gastrointestinal Stromal Tumor
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate.
- Trial name
- NCT00265798
- Testing
- Sorafenib Tosylate
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
SDH Gene Mutation, Gastrointestinal Stromal Tumor
PH 2 Pemigatinib in SDH-deficient GIST
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST).
- Trial name
- PEMIGIST (NCT07434843)
- Testing
- Pemigatinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dana-Farber Cancer Institute
GIST
Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST
This is a US, multicenter, open-label expanded access program to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program.
- Trial name
- NCT03862885
- Testing
- Avapritinib
- Sponsor
- Blueprint Medicines Corporation
Gastrointestinal Stromal Tumor
Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor
To elucidate the prognosis of women with non-gastric primary gastrointestinal stromal tumors.
- Trial name
- NCT04256226
- Testing
- Tumor excision
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- Far Eastern Memorial Hospital
3rd Line GIST
A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
The purpose of this study is to determine a maximum tolerated dose and/or recommended phase 2 dose of a combination of imatinib and BYL719 in the treatment of 3rd line GIST patients.
- Trial name
- NCT01735968
- Testing
- ST571 + BYL719
- Where
- 11 sites in United States, Belgium and 6 more
- Volunteers
- 56 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably.
- Trial name
- NCT00274885
- Testing
- oxaliplatin, management of therapy complications
- Where
- 6 sites in France
- Volunteers
- 58 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms
Gastrointestinal Anastomosis Using MonoPlus® Suture
The primary aim of this study is to collect clinical data on the performance of MonoPlus® suture applied in routine clinical practice.
- Conditions
- Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms, Digestive System Neoplasm, Stomach Tumor
- Trial name
- GASTROMO (NCT04811833)
- Where
- 2 sites in Spain
- Sponsor
- Aesculap AG
Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma
Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy
The FIBROPANC-1 investigates the feasibility and safety of preoperative stereotactic radiotherapy of 4cm pancreas in patients undergoing pancreatoduodenectomy at high risk (>25%) of developing post operative pancreatic fistula…
- Conditions
- Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma, Pancreas Neoplasm, Distal Cholangiocarcinoma
- Trial name
- FIBROPANC-1 (NCT05641233)
- Testing
- Stereotactic radiotherapy
- Where
- 2 sites in Netherlands
- Volunteers
- 33 people
- Sponsor
- Erasmus Medical Center
Digestive Cancer, Metastatic Colorectal Cancer
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic…
- Conditions
- Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma, GIST
- Trial name
- TARGETMONITO (NCT05443087)
- Testing
- Blood sampling to build population pharmacokinetics model
- Where
- 29 sites in France
- Volunteers
- 330 people
- Sponsor
- UNICANCER
Drug Interaction Potential
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
This study has two parts. Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam and tolbutamide, respectively, as probe agents.
- Trial name
- NCT03291288
- Testing
- Tolbutamide, Midazolam, Pexidartinib
- Where
- 11 sites in United States, Netherlands and 2 more
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Gastrointestinal Stromal Tumors
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
The goal of this clinical trial is to learn what dose of the drug fampridine can be given safely together with imatinib (Gleevec) in patients with gastrointestinal stromal tumor (GIST) with a DNA mutation in exon 11 of the KIT…
- Trial name
- NCT07171203
- Testing
- Imatinib, Fampridine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Diego
Gastrointestinal Stromal Tumor, Sarcoma
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced, metastatic, or recurrent soft tissue sarcomas. SU5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor.
- Trial name
- NCT00005862
- Testing
- semaxanib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Submucosal Tumor of Gastrointestinal Tract, Gastrointestinal Stromal Tumor (GIST)
Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction
This study is a single-center, prospective, single-arm, exploratory clinical study (phase II exploratory trial). No parallel control group was established in the study, and all subjects who met the inclusion criteria underwent a…
- Trial name
- SAVE-GEJ (NCT07550582)
- Testing
- laparoscopic and endoscopic cooperative surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Colorectal Carcinoma, Rectal Prolapse
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
Robotic assisted surgery has been performed for more than two decades with good success and safety profile. However, there was only one dominating robotic surgical system available in the past which led to high cost for robotic…
- Conditions
- Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
- Trial name
- NCT06926374
- Testing
- Robotic surgery using the Sentire Surgical System
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong